Functional improvement of dystrophic muscle by myostatin blockade
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Mice and cattle with mutations in the myostatin (GDF8) gene show a marked increase in body weight and muscle mass, indicating that this new member of the TGF-beta superfamily is a negative regulator of skeletal muscle growth. Inhibition of the myostatin gene product is predicted to increase muscle mass and improve the disease phenotype in a variety of primary and secondary myopathies. We tested the ability of inhibition of myostatin in vivo to ameliorate the dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD). Blockade of endogenous myostatin by using intraperitoneal injections of blocking antibodies for three months resulted in an increase in body weight, muscle mass, muscle size and absolute muscle strength in mdx mouse muscle along with a significant decrease in muscle degeneration and concentrations of serum creatine kinase. The functional improvement of dystrophic muscle by myostatin blockade provides a novel, pharmacological strategy for treatment of diseases associated with muscle wasting such as DMD, and circumvents the major problems associated with conventional gene therapy in these disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The interest in myostatin was generated by recent studies where antibodies for myostatin were created and administered to adult rodents, which resulted in an increase in body mass, muscle mass, muscle size, and strength [11,12].”
From Effects of methoxyisoflavone, ecdysterone, and sulfo-polysaccharide supplementation on training adaptations in resistance-trained males (2006) · cites this paper as [12]
Citations
Cites
Textbook of Medical Physiology
(1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-6-1363_2 · Cited by 9,749
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
TEXTBOOK OF MEDICAL PHYSIOLOGY
GUYTON, A. C. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196701000-00031 · Cited by 2,837
Dystrophin expression in the mdx mouse restored by stem cell transplantation
Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., Flint, A. F., Kunkel, L. M., & Mulligan, R. C. (1999) · Nature · doi:10.1038/43919 · Cited by 1,802 · cited 1×
“In comparison with conventional transgenic, cell and gene therapy approache”
BackgroundX chromosome-linked muscular dystrophy (mdx) in the mouse
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1189 · Cited by 1,765
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 1×
“Alterations in Smad 2 and 3 phosphorylation would be predicted to regulate the formation of Smad complexes, their nuclear translocation and transcriptional regulation of genes associated with commitment of muscle progenitor”
BackgroundA deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526 · cited 1×
“The regimen did not completely reverse dystrophic changes; physiological parameters evaluated by ex vivo tests, such as susceptibility to damage by lengthening contraction”
BackgroundAhima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Self-citation
Research works printed but not linked: 2
- Jalenak, M. et al. Transcriptional changes arising from in vivo inhibition of myostatin. J. Neurol. Sci. 199 (suppl)., S83 (2002)
- Engel, A. G. & Franzini-Armstrong, C. Myology (McGraw-Hill, New York, 1994)
Cited by
Items 801–853 of 853
Novel Therapeutic Strategy for the Prevention of Bone Fractures
Hamrick, M. W. (2014) · Defense Technical Information Center (DTIC) · doi:10.21236/ada614236
2. Molecular Mechanisms and Therapeutic Strategies for Muscular Dystrophies
Toda, T. (2016) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.105.77a
Takayama, K. (2022) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c22-00048
Myostatin Expression in MDS Patients with Wasting Syndrome
Garlemou, K., Alexandrakis, M. G., Karras, G., Kyriakou, D. S., & Kourelis, T. (2022) · Asian Journal of Biological Sciences · doi:10.3923/ajbs.2022.40.48
Kochergin-Nikitsky, K. S., Smirnikhina, S., & Лавров, А. В. (2024) · Neuromuscular Diseases · doi:10.17650/2222-8721-2024-14-1-51-62
Kulkarni, P., Pandey, R., Kumar, A., Arya, N., & Das, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15968-8.00017-x
Investigação de novos mecanismos moleculares protetores na Distrofia Muscular de Duchenne
Esposito, J. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.41.2024.tde-24012025-123428
Lu‐Nguyen, N., Dickson, G., & Malerba, A. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4730-1_20
Isolation and Culture of Primary Myoblasts from Humans and Mice
Leite, F. D. S., & Gussoni, E. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4811-7_10
He, H.-X., Zhu, K.-C., Liu, B.-S., Guo, H., Zhang, N., Xian, L., Zhu, T., Zhang, D., & Yang, M. (2025) · Fish Physiology and Biochemistry · doi:10.1007/s10695-025-01606-8
“Mstn1 , which is alternatively called Growth Differentiation Factor 8 (GDF-8), serves as a key player in muscle development and growth (Bogdanovich et al. 2002; Schuelke et al. 2004; Siriett et al. 2006; Yang et al. 2023).”
The Effect of Myostatin-antagonist4 on a Severe Muscle Burn Injury
Laurenson, R. M. (2009) · Research Commons (University of Waikato)
The Effects Of Maternal Immunization Against Myostatin On Post-hatch Chicken Growth
Mishra, R. K. (2021) · ScholarSpace (University of Hawaii at Manoa)
Correction of Dystrophin gene with Homology Directed Repair
1991, G. R. Ó. (2016) · Skemman
Pharmacological intervention for tumor-induced cachexia
Karthikaisamy, V., Klingenspor, M., & München, T. U. (2023)
Nouvelles stratégies thérapeutiques des dystrophies musculaires
Krahn, M., Lévy, N., Danièle, N., Richard, I., & Bartoli, M. (2008) · Revue du Rhumatisme · doi:10.1016/j.rhum.2007.12.001
The therapeutic potential of Myoki, a novel peptide in muscle atrophy: mechanisms and applications
Kim, E. M., Kim, S. S., Hyun, Y. G., Lee, S. Y., & Chung, Y. J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1663850
Yamakado, T., Ishikawa, Y., Ise, K., Wang, L., Oda, Y., Tsuda, M., Kimura, T., Nagao, M., Ito, M., Tanaka, S., et al. (2026) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.70068
“For example, myostatin inhibitors, such as domagrozumab, primarily induce muscle fibre hypertrophy [45, 46].”
Approches de thérapies géniques pour des maladies neuromusculaires
Moulay, G. (2010) · theses.fr (ABES) · doi:10.70675/e7c5d58ez3cc2z4a72z8d92z6b13cb1ea30c · Cited by 1
C. elegans, un outil de criblage pour la recherche de traitements contre les maladies rares
Giacomotto, J. (2010) · theses.fr (ABES) · doi:10.70675/01f31096zdc34z4639zbfc6z8ff80973680c
Evaluation de régulateurs positifs de la croissance musculaire chez un modèle dystrophique murin
Guiraud, S. (2011) · theses.fr (ABES) · doi:10.70675/0c021d5bz542bz442bzbb0cz66c3d0b5c31d
Implication des céramides dans l'atrophie musculaire
Larichaudy, J. D. (2012) · theses.fr (ABES) · doi:10.70675/b97ff403z6fa7z464fzb67czaa56e3753d9e
Skeletal muscle growth and maintenance depend on BMP signaling
Schirwis, E. (2014) · theses.fr (ABES) · doi:10.70675/7234357bz1f9dz4a42za02cz799ec1dedf12
Lorant, J. (2016) · theses.fr (ABES) · doi:10.70675/87808109zf52cz4402z9da6z81f59cf2d98e · Cited by 1
The function of Activin receptor type IIB signaling in adult skeletal muscle
Relizani, K. (2014) · theses.fr (ABES) · doi:10.70675/20978d43z02f0z4a1ezb428zf5dab86d9abf
Evaluation de peptides régulateurs positifs de la masse musculaire
Shafey, N. E. (2014) · theses.fr (ABES) · doi:10.70675/58061adbze0dfz4309zafc4za044df2c7bed
Régulation des fonctions musculaires par les glucocorticoïdes et les androgènes
Ueberschlag-Pitiot, V. (2016) · theses.fr (ABES) · doi:10.70675/a58edbdfz7b09z4c07z8fcfz350445fbb29c
Parenté, A. (2019) · theses.fr (ABES) · doi:10.70675/3d9a23f5z3546z46f1z957cz5d167994539d
Etude des isoformes du gène PGC-1a dans le développement musculaire chez le bovin
Bamba‐Funck, J. (2018) · theses.fr (ABES) · doi:10.70675/ffb388c0z6084z4cf4z83bez9c767829ded2
Le développement préclinique des tcDNA pour la Dystrophie Musculaire de Duchenne
Aupy, P. (2019) · theses.fr (ABES) · doi:10.70675/308d569bzf97az413bz805fzc8aaca0427df
Yu, Y., He, Y., Wang, Y., Wu, C., Zhou, R., Chen, F., & Ma, W. (2026) · The FASEB Journal · doi:10.1096/fj.202601360r · Cited by 1
“Diverse targeting ap-proaches—including monoclonal antibodies and engineered decoy receptors—consistently improved mass and function in preclinical studies [123, 125, 126], with several candidates advancing to early-phase clinical trials [127, 128].”
ANDROGENIC REGULATION OF SEX DIFFERENCES IN ADAPTATIONS TO AGING AND EXERCISE IN RATS
Barsky, S. T. (2024) · TSpace (University of Toronto)
Ling, L., Cao, M.-X., Farhab, M., Kyaw, P. O., Zhao, S.-Q., Zhao, Y., Chen, F.-L., Sohail, T., Ahmad, E., Cao, S.-X., et al. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-02002-y
“…livestock species such as cattle and sheep, characterized by significantly increased muscle mass and hypertrophy of muscle fibers, making it an important target for genetic improvement of muscle traits in agricultural animals (Clop et al. 2006; Bogdanovich et al. 2002; Grobet et al. 1997a, b).”
Bogdanovich, S., Pistilli, E. E., & Khurana, T. S. (2026) · Muscles · doi:10.3390/muscles5030058
“We have previously demonstrated that JA16 monoclonal antibody-mediated myostatin blockade resulted in an improvement in the dystrophic phenotype in 1-month-old mdx mice [55].”
InfluentialSelf-citationFunctional improvement of dystrophic muscle by utrophin gene editing
Ghosh, T., Ahamed, S. K. T., Xu, J., Han, X., Tombácz, I., Chaboub, L. S., Mitchell, M. J., Weissman, D., & Khurana, T. S. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201857
Self-citationBindingDB Entry 50010478: Discovery of a follistatin-derived myostatin inhibitory peptide.
BindingDB (2021) · UC San Diego · doi:10.7270/q2g73j8q
BindingDB (2024) · UC San Diego · doi:10.7270/q2q81j8g
BindingDB (2021) · UC San Diego · doi:10.7270/q2v1287x
BindingDB Entry 50010290: Design and synthesis of potent myostatin inhibitory cyclic peptides.
BindingDB (2021) · UC San Diego · doi:10.7270/q2w099fn
Peripheral Signaling Pathways Involved in Muscle Loss
Rüegg, M. A., Possekel, S., & Meier, T. (2005) · CRC Press eBooks · doi:10.1201/9781420048957.ch29
Mechanismen der Steuerung der Embryonalentwicklung
Christ, B., & Brand‐Saberi, B. (2005) · Springer eBooks · doi:10.1007/3-540-26524-4_1
Metadata
- Authors
- Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S.
- Affiliations
- University of Pennsylvania (US)
- Pfizer (United States) (US)
- Corresponding author
- Khurana, Tejvir S.
- Venue
- Nature
- Published
- 2002-11
- Volume
- 420
- Issue
- 6914
- Pages
- 418-421
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2083700023
- Semantic Scholar
- 590fb54cd1f2d89d44f4e1ad999be802dc756277
- Cited by
- 831
- References
- 31
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 19 · 2023: 15 · 2022: 21 · 2021: 20 · 2020: 23 · 2019: 32 · 2018: 23 · 2017: 34 · 2016: 28 · 2015: 43 · 2014: 34 · 2013: 38 · 2012: 48
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Keywords
- myostatin, Duchenne muscular dystrophy, mdx mice, muscle atrophy, blocking antibodies, muscle mass, muscle strength, muscle degeneration, creatine kinase, TGF-beta superfamily, skeletal muscle growth
- MeSH terms
- Animals, Antibodies, Body Weight, Creatine Kinase, Male, Muscular Dystrophy, Animal, Organ Size, Transforming Growth Factor beta, Mice, Inbred mdx, Muscle, Skeletal, Muscle Fibers, Skeletal, Muscular Dystrophy, Duchenne, Mice, Myostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.